Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment
暂无分享,去创建一个
E. Dejesus | P. Keiser | Allan E. Rodriguez | G. E. Pakes | M. Sension | Jaime E. Hernandez | Anne Shachoy-Clark | J. Snidow | V. Williams | Julie W Fleming | J. Olliffe | J. Wakeford | J. F. Olliffe | J. Fleming | Jeffrey F. Olliffe